SG143977A1 - Methods and compositions for assessment of pulmonary function and disorders - Google Patents

Methods and compositions for assessment of pulmonary function and disorders

Info

Publication number
SG143977A1
SG143977A1 SG200507795-3A SG2005077953A SG143977A1 SG 143977 A1 SG143977 A1 SG 143977A1 SG 2005077953 A SG2005077953 A SG 2005077953A SG 143977 A1 SG143977 A1 SG 143977A1
Authority
SG
Singapore
Prior art keywords
disorders
methods
pulmonary function
assessment
compositions
Prior art date
Application number
SG200507795-3A
Other languages
English (en)
Inventor
Robert Peter Young
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of SG143977A1 publication Critical patent/SG143977A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG200507795-3A 2001-06-05 2002-06-05 Methods and compositions for assessment of pulmonary function and disorders SG143977A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ51216901 2001-06-05
NZ51301601 2001-07-17
NZ51427501 2001-09-18

Publications (1)

Publication Number Publication Date
SG143977A1 true SG143977A1 (en) 2008-07-29

Family

ID=27353936

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200507795-3A SG143977A1 (en) 2001-06-05 2002-06-05 Methods and compositions for assessment of pulmonary function and disorders

Country Status (15)

Country Link
US (2) US20040219548A1 (de)
EP (2) EP1402073B1 (de)
JP (1) JP2004532640A (de)
AT (1) ATE353976T1 (de)
AU (1) AU2002323841B2 (de)
CA (1) CA2449647A1 (de)
CY (1) CY1107625T1 (de)
DE (1) DE60218162T2 (de)
DK (1) DK1402073T3 (de)
ES (1) ES2282444T3 (de)
HK (1) HK1065336A1 (de)
NZ (1) NZ545283A (de)
PT (1) PT1402073E (de)
SG (1) SG143977A1 (de)
WO (1) WO2002099134A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087249A1 (ja) * 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
WO2005092383A1 (ja) * 2004-03-26 2005-10-06 Takeda Pharmaceutical Company Limited 呼吸器疾患の予防・治療剤
GB0508023D0 (en) * 2005-04-21 2005-05-25 Univ Nottingham Pulmonary disease marker
CA2608142A1 (en) * 2005-05-10 2006-11-16 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
JP2006314315A (ja) * 2005-05-10 2006-11-24 Synergenz Bioscience Ltd 肺の機能と異常を調べるための方法と組成物
AU2006248200A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
CA2608161A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
US7933722B2 (en) * 2005-05-20 2011-04-26 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
WO2008048119A2 (en) * 2006-10-17 2008-04-24 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
WO2010105235A2 (en) 2009-03-12 2010-09-16 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
WO2009139648A2 (en) * 2008-05-12 2009-11-19 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
CN111826383B (zh) * 2020-07-16 2022-08-02 昆明理工大学 丹波黑大豆超氧化物歧化酶基因在提高植物铝耐受性中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829052A (en) * 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US5827662A (en) * 1989-06-23 1998-10-27 The Trustees Of The University Of Pennsylvania Methods for detecting genetic mutations resulting in protease inhibitor insufficiencies
US5844108A (en) * 1990-06-22 1998-12-01 Roche Molecular Systems, Inc. Primers targeted to NAT2 gene for detection of poor metabolizers of drugs
EP1262493A1 (de) * 1992-10-29 2002-12-04 Bayer Corporation Diagnostischer Test spezifisch für die latente Matrix Metalloproteinase no. 9
US5455262A (en) * 1993-10-06 1995-10-03 Florida State University Mercaptosulfide metalloproteinase inhibitors
JPH07303482A (ja) * 1993-11-30 1995-11-21 Fuji Yakuhin Kogyo Kk 新規なメタロプロテアーゼおよびそれをコードするｄｎａ
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
KR100231230B1 (ko) * 1995-08-08 1999-11-15 우에노 도시오 히드록삼산 유도체(hydroxamic acid derivatives)
AU718439B2 (en) * 1995-09-21 2000-04-13 Genentech Inc. Human growth hormone variants
US5837492A (en) * 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
DE69625678T3 (de) * 1995-12-18 2006-11-09 The University Of Utah Research Foundation, Salt Lake City Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
US5932579A (en) * 1996-06-18 1999-08-03 Affymax Technologies N.V. Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use
US6060283A (en) * 1996-06-27 2000-05-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor)
US6057297A (en) * 1996-08-06 2000-05-02 Polifarma S.P.A. Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof
US5773430A (en) * 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US20060122373A1 (en) * 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
EP0975752A1 (de) * 1997-04-29 2000-02-02 Regeneron Pharmaceuticals, Inc. Menschliches cerberusprotein
US20050282198A1 (en) * 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US5935852A (en) * 1997-07-03 1999-08-10 Genetics Institute, Inc. DNA molecules encoding mammalian cerberus-like proteins
US6211209B1 (en) * 1997-08-08 2001-04-03 Warner-Lambert Company Method of inhibiting connective tissue degradation
CN1222615C (zh) * 1997-12-16 2005-10-12 帝人株式会社 根据人呼吸道胰蛋白酶基因多态性分析体质
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6117869A (en) * 1998-08-04 2000-09-12 Warner-Lambert Company Compounds for and methods of inhibiting matrix metalloproteinases
US6183963B1 (en) * 1998-10-23 2001-02-06 Signalgene Detection of CYP1A1, CYP3A4, CYP2D6 and NAT2 variants by PCR-allele-specific oligonucleotide (ASO) assay
US6677442B1 (en) * 1999-10-29 2004-01-13 University Of Kentucky Research Foundation Nucleic acid encoding human REV1 protein
US6187587B1 (en) * 2000-03-02 2001-02-13 Isis Pharmaceuticals, Inc. Antisense inhibition of e2f transcription factor 1 expression
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6716581B2 (en) * 2000-03-31 2004-04-06 University Of Southern California Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility
US20050064454A1 (en) * 2000-06-05 2005-03-24 Young Paul E. Cancer gene determination and therapeutic screening using signature gene sets
AU2001277997A1 (en) * 2000-07-25 2002-02-05 Dzgenes, L.L.C. Diagnostic polymorphisms for the tgf-beta1 promoter
US6673549B1 (en) * 2000-10-12 2004-01-06 Incyte Corporation Genes expressed in C3A liver cell cultures treated with steroids
US20040241714A1 (en) * 2003-02-04 2004-12-02 Branch Robert A. Methods of assessment of drug metabolizing enzymes
CA3050151C (en) * 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof

Also Published As

Publication number Publication date
CA2449647A1 (en) 2002-12-12
US20040219548A1 (en) 2004-11-04
DE60218162T2 (de) 2007-10-31
US20120142000A1 (en) 2012-06-07
NZ545283A (en) 2008-01-31
PT1402073E (pt) 2007-05-31
EP1402073A4 (de) 2005-11-02
HK1065336A1 (en) 2005-02-18
JP2004532640A (ja) 2004-10-28
WO2002099134B1 (en) 2003-02-13
WO2002099134A1 (en) 2002-12-12
AU2002323841B2 (en) 2008-05-22
CY1107625T1 (el) 2013-03-13
ATE353976T1 (de) 2007-03-15
DK1402073T3 (da) 2007-06-11
EP1402073B1 (de) 2007-02-14
EP1402073A1 (de) 2004-03-31
ES2282444T3 (es) 2007-10-16
DE60218162D1 (de) 2007-03-29
EP1801240A1 (de) 2007-06-27

Similar Documents

Publication Publication Date Title
CY1107625T1 (el) Μεθοδοι και συνθεσεις για αποτιμηση πνευμονικης λειτουργιας και διαταραχων
Askeland et al. Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington’s disease patients
Newby Metalloproteinase production from macrophages–a perfect storm leading to atherosclerotic plaque rupture and myocardial infarction
WO2008048120A3 (en) Methods and compositions for assessment of pulmonary function and disorders
Parker et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons
Ruchirawat et al. Exposure to benzene in various susceptible populations: co-exposures to 1, 3-butadiene and PAHs and implications for carcinogenic risk
DE602005010970D1 (de) Indol-derivate und ihre verwendung als kinase-hemmer, insbesondere ikk2-hemmer
WO2007120480A3 (en) Systems and methods for predicting effectiveness in the treatment of psychiatric disorders, including depression
WO2006060646A3 (en) Cell microarray for profiling of cellular phenotypes and gene function
ATE446385T1 (de) Polymorphismen im nod2/card15 gen
NO20070467L (no) Pyrrolopyrimidin og pyrrolopyridinderivater substituert med tetrahydropyridin som CRF antagonister
WO2007050794A3 (en) The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
Hyndman et al. Effect of heterozygosity for the methionine synthase 2756 A--> G mutation on the risk for recurrent cardiovascular events.
WO2006123955A3 (en) Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
WO2006121351A3 (en) Methods and compositions for assessment of pulmonary function and disorders
Dahl et al. Asthma and COPD in cystic fibrosis intron-8 5T carriers. A population-based study
Schulz et al. Single nucleotide polymorphisms in long noncoding RNA, ANRIL, are not associated with severe periodontitis but with adverse cardiovascular events among patients with cardiovascular disease
WO2004099382A3 (en) Methods for global profiling gene regulatory element activity
WO2006013561A3 (en) Compositions and methods for diagnosing and treating post traumatic stress disorder
Doki et al. Effects of CYP2D6 genotypes on age‐related change of flecainide metabolism: involvement of CYP1A2‐mediated metabolism
Korotkova et al. Variants of gene for microsomal prostaglandin E2 synthase show association with disease and severe inflammation in rheumatoid arthritis
Shoeb et al. Silica inhalation altered telomere length and gene expression of telomere regulatory proteins in lung tissue of rats
EP2443258A4 (de) Verfahren und zusammensetzungen zur beurteilung von lungenfunktion und lungenleiden
WO2003064600A3 (en) The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
Stankovic et al. Gene‐environment interaction between the MMP9 C–1562T promoter variant and cigarette smoke in the pathogenesis of chronic obstructive pulmonary disease